cagrilintide semaglutide cagrisema phase 3 results 2024 2025 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study cagrisema cagrilintide semaglutide phase 3

Large prospective cohorts and mechanistic human investigations are therefore required to validate this link

Common Side Effects The majority of adverse effects are mild and temporary, resolving within a few weeks as patients acclimate to the therapeutic regimen

Weight struggles and metabolic issues can lead to feelings of frustration, low self-esteem, and depression

While it has not yet been approved and the exact eligibility criteria is not final, current clinical trials relate to patient groups with: adults with obesity adults who are overweight and also have a weight-related health condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or heart disease

A., Klaassen, C

Furthermore, a preclinical study demonstrated that circulating MPs may impair brain function via immune-mediated vascular occlusion (Huang et al., 2025)